- Home
- Editorial
- News
- Practice Guidelines
- Anesthesiology Guidelines
- Cancer Guidelines
- Cardiac Sciences Guidelines
- Critical Care Guidelines
- Dentistry Guidelines
- Dermatology Guidelines
- Diabetes and Endo Guidelines
- Diagnostics Guidelines
- ENT Guidelines
- Featured Practice Guidelines
- Gastroenterology Guidelines
- Geriatrics Guidelines
- Medicine Guidelines
- Nephrology Guidelines
- Neurosciences Guidelines
- Obs and Gynae Guidelines
- Ophthalmology Guidelines
- Orthopaedics Guidelines
- Paediatrics Guidelines
- Psychiatry Guidelines
- Pulmonology Guidelines
- Radiology Guidelines
- Surgery Guidelines
- Urology Guidelines
Vitamin D supplementation beneficial for dry eye disease patients
Vitamin D supplements increase efficacy of lubricant eye preparations and help patients suffering from dry eye disease.
The effect of topical carbomer-based lipid-containing artificial tears (CLAT) and hyaluronate (HU) in dry eye disease (DED) was dependent on serum 25-hydroxyvitamin D levels, and vitamin D supplementation enhanced the efficacy of topical lubricants for treatment of dry eye. These are the results from a retrospective, observational cohort study published in the journal Cornea.
Vitamin D supplements prevent rickets in children and osteomalacia in adults. Together with calcium, vitamin D also helps protect older adults from osteoporosis.
Vitamin D has other roles in the body, including modulation of cell growth, neuromuscular and immune function, and reduction of inflammation.
- After 2 weeks, OSDI and visual analog pain scale scores decreased in both VDD and non-VDD groups after application of topical CLAT and HU compared with baseline.
- There was no improvement in TBUT, corneal fluorescein staining score and lid hyperaemia from baseline in the VDD group by topical CLAT and HU, whereas those in the non-VDD group showed significant improvement from baseline (3.2 ± 1.7 vs 4.1 ± 2.2; 0.5 ± 0.7 vs 0.4 ± 0.6, and 2.2 ± 0.8 vs 1.9 ± 0.7, respectively).
- There was a significant improvement in OSDI score, TBUT, and lid margin hyperemia in the IM group after cholecalciferol supplementation compared with pre-treatment (33.2 ± 23.2 vs 28.5 ± 21.9; 3.5 ± 1.9 vs 6.0 ± 2.5 and 2.2 ± 0.7 vs 1.2 ± 0.8).
Also Read: Migraine patients at risk for dry eye: JAMA
For detailed study log on to 10.1097/ICO.0000000000001822
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd